Home | My Profile | Contact Us
Research Trends Products  |   order gateway  |   author gateway  |   editor gateway  
Register | Forgot Password

Author Resources
 Author Gateway
 Article submission guidelines

Editor Resources
 Editor/Referee Gateway

 Regional Subscription Agents/Distributors
Current Topics in Peptide & Protein Research   Volumes    Volume 7 
Neuropeptides and classical neurotransmitters involved in Parkinson’s disease
Felix-Martin Werner, Rafael Coveñas
Pages: 75 - 84
Number of pages: 10
Current Topics in Peptide & Protein Research
Volume 7 

Copyright © 2005 Research Trends. All rights reserved


Parkinson’s disease is a neurodegenerative illness that to date cannot be treated curatively. The pathophysiology of the illness is known: in the extrapyramidal system there is a neurotransmitter imbalance in the sense of a lack of dopamine and a surplus of acetylcholine. Moreover, in this neuronal system two presynaptic inhibitory neurotransmitters are involved: GABA (which is increased) and glutamate (which is decreased). Thus, different treatments have been attempted in Parkinson’s disease since the neuronal circuits containing classically known neurotransmitters are altered in the extrapyramidal system.

It is also known that in addition to the above neurotransmitters, other neuropeptides are altered in Parkinson’s disease; for example altered concentrations of substance P, neuropeptide Y and thyrotropin-releasing hormone are found in the extrapyramidal system, and increased concentrations of galanin in the basal nucleus of Meynert have been demonstrated. In the light of this, our aim here is to review the alterations found in the concentrations of classical neuro-transmitters and neuropeptides in Parkinson’s disease. In order to optimize the treatment of Parkinson’s disease, we pose the question of whether an early diagnosis and an earlier onset of therapy with different drugs might improve the course of the disease. We shall discuss whether or not treatment with neuropeptide agonists or antagonists, as supplementary therapy, might improve the symptoms of Parkinson’s disease.

Buy this Article


Buy this article
Buy this volume
Subscribe to this title
Shopping Cart

Quick Links
Search Products
Browse in Alphabetical Order : Journals
Browse by Subject Classification : Journals

Ordering Information Ordering Information
Downloadable forms Downloadable Forms